



This is a repository copy of *12670 CHAMPAIN study: initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/218062/>

Version: Published Version

Proceedings Paper:

Prete, A., Theiler-Schwetz, V., Arlt, W. et al. (13 more authors) (2024) 12670 CHAMPAIN study: initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society

<https://doi.org/10.1210/jendso/bvae163.132>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Abstract citation ID: bvae163.132

**Adrenal (Excluding Mineralocorticoids)
12670****CHAMPAIN Study: Initial Results From A Phase II Study Of Efficacy, Safety And Tolerability Of Modified-release Hydrocortisones: Chronocort[®] (Efmody[®]) Versus Plenadren[®], In Primary Adrenal Insufficiency**

Alessandro Prete¹, Verena Theiler-Schwetz, Dr, MD²,
 Wiebke Arlt, MD DSc FRCP FMedSci³, Irina Oana Chifu⁴,
 Birgit Harbeck, MD^{5,6}, Catherine Napier, MBBS, MRCP, PhD⁷,
 John D. C. Newell-Price, MD, PhD, FRCP⁸, Aled Rees, MD, PhD⁹,
 Nicole Reisch, MD¹⁰, Gunter Karl Stalla, MD¹¹,
 Naila Aslam, BSc MBBS MRCPCH¹², Helen Coope, PhD¹³,
 Kerry Maltby, BSc Hons¹⁴, John Porter, MD¹⁵,
 Jo Quirke, BSc (Hons)¹⁶,
 and Richard John M Ross, MBBS, FRCP, MD⁸

¹University of Birmingham, BIRMINGHAM, United Kingdom;
²University of Birmingham, Birmingham, United Kingdom; ³MRC
 Laboratory of Medical Sciences (LMS), London, United Kingdom;
⁴Universitätsklinikum Wrzburg, Wrzburg, Germany; ⁵University
 Hamburg, Amedes experts, Hamburg, Germany; ⁶Department of
 Medicine, University Medical Center Hamburg-Eppendorf,
 Hamburg, Germany; ⁷Endocrine Department, Royal Victoria
 Infirmary, Newcastle Upon Tyne, United Kingdom; ⁸University of
 Sheffield, Sheffield, United Kingdom; ⁹Cardiff University, Cardiff,
 United Kingdom; ¹⁰Med. Klinik IV, Munich, Germany;
¹¹Medicover Neuroendocrinology, Munich, Germany; ¹²Diurnal
 Ltd, a Neurocrine Biosciences company, Cardiff, United Kingdom;
¹³NEUROCRINE BIOSCIENCES, rugeley, United Kingdom;
¹⁴Diurnal Ltd, a Neurocrine Biosciences Company, Cardiff, United
 Kingdom; ¹⁵Diurnal Ltd., Cardiff, United Kingdom; ¹⁶Diurnal,
 Cardiff, United Kingdom

Disclosure: **A. Prete:** Research Investigator; Self; Diurnal. **V. Theiler-Schwetz:** Research Investigator; Self; Diurnal. **W. Arlt:** Research Investigator; Self; Diurnal. **I.O. Chifu:** Research Investigator; Self; Diurnal. **B. Harbeck:** Research Investigator; Self; Diurnal. **C. Napier:** Research Investigator; Self; Diurnal. **J.D. Newell-Price:** Research Investigator; Self; Diurnal. **A. Rees:** Research Investigator; Self; Diurnal. **N. Reisch:** Research Investigator; Self; Diurnal. **G.K. Stalla:** Research Investigator; Self; Diurnal. **N. Aslam:** Employee; Self; Diurnal. **H. Coope:** Employee; Self; Diurnal. **K. Maltby:** Employee; Self; Diurnal. **J. Porter:** Employee; Self; Diurnal. **J. Quirke:** Employee; Self; Diurnal. **R.J. Ross:** Consulting Fee; Self; Diurnal.

Background: Current glucocorticoid replacement regimens for patients with primary adrenal insufficiency (PAI) mean patients wake with either low or undetectable cortisol levels[1], associated with fatigue and a reduced quality of life (QoL)². Plenadren[®] (Takeda, UK) is a once-daily modified-release formulation of hydrocortisone that replaces daytime cortisol levels whereas Chronocort[®] (modified-release hydrocortisone hard capsules, Diurnal, UK) when taken twice-daily, has been shown to replicate the normal overnight rise in serum cortisol concentration and provide physiological levels throughout the day. We have undertaken a double-blind, double-dummy, two-way cross-over, randomised, phase II study of efficacy, safety and tolerability of

modified-release hydrocortisones: Chronocort[®] Versus Plenadren[®]. **Aim:** To test the hypothesis that Chronocort[®] provides more physiological waking cortisol levels than Plenadren[®]. **Methodology:** The study was conducted across 8 sites in the UK and Germany. Male and female patients, aged ≥ 18 with confirmed PAI (defined as morning pre-dose cortisol < 50 nMol/l) on stable therapy over the preceding three months and not currently treated with Chronocort[®]/Plenadren[®]. Participants with congenital adrenal hyperplasia (CAH), secondary or tertiary AI were excluded. Each participant was randomised on a 1:1 basis to either; treatment sequence I (Chronocort[®] first) or treatment sequence II (Plenadren[®] first) taking a 25mg total daily dose for 4 weeks; either Plenadren[®] 25mg in the morning or Chronocort[®] 10mg in the morning and 15mg at night with the associated dummy preparation followed immediately by the other treatment. The pre-dose morning serum cortisol level was assayed at baseline and after each treatment period. A physiological morning cortisol level was defined as a pre-dose level of > 140 nMol/L. Secondary measures included: morning fatigue measured using the Multidimensional Assessment of Fatigue (MAF) questionnaire and the PROMIS[®] 7b questionnaire; QoL was assessed using the EuroQol 5-level Standardised Health Questionnaire (EQ-5D-5LTM); Health-related Quality of Life in Addison's disease (AddiQoL) questionnaire and the 36-Item Short Form Health Survey (SF-36[®]) questionnaire. **Results:** Of 49 evaluable participants with PAI, 45 achieved a physiological morning cortisol after four weeks of Chronocort[®] compared with 2 after four weeks of Plenadren[®] ($P < 0.0001$). The mean (standard deviation) waking cortisol was 422.85 (203.50) vs 36.98 (113.87), respectively. **Conclusion:** Chronocort[®] provides more physiological waking cortisol levels than Plenadren[®]. Further analysis will test the hypothesis that waking with physiological cortisol levels improves fatigue and QoL in patients with PAI. 1.Mah PM, et al. Clin Endocrinol (Oxf). 2004;61(3):367-75.2.Wichers M, et al. Clin Endocrinol (Oxf). 1999;50(6):759-65.

Presentation: 6/3/2024